* Viracta Therapeutics Inc VIRX.OQ reported a quarterly
adjusted
loss of 27 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -33 cents. The mean expectation of two analysts
for the quarter was for a loss of 24 cents per share. Wall
Street expected results to range from -28 cents to -21 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Viracta Therapeutics Inc's reported EPS for the quarter
was a
loss of 27 cents.
* The company reported a quarterly loss of $10.55 million.
* Viracta Therapeutics Inc shares had fallen by 23.6% this
quarter and lost 69.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 3.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "hold."
Wall Street's median 12-month price target for Viracta
Therapeutics Inc is 3.50
This summary was machine generated from LSEG data November 13 at
02:16 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.24 -0.27 Missed
Jun. 30 2024 -0.37 -0.25 Beat
Mar. 31 2024 -0.35 -0.23 Beat
Dec. 31 2023 -0.31 -0.35 Missed